AAPL315.32-0.90 (-0.28%) ▼|ABBV248.08-1.83 (-0.73%) ▼|ABT93.93-0.47 (-0.50%) ▼|ACN135.23-3.83 (-2.75%) ▼|ADBE223.64+0.99 (+0.44%) ▲|AMAT602.50+13.84 (+2.35%) ▲|AMD557.89+11.17 (+2.04%) ▲|AMGN363.39-0.23 (-0.06%) ▼|AMT168.59+3.59 (+2.18%) ▲|AMZN245.34-1.70 (-0.69%) ▼|AVGO399.97-1.14 (-0.28%) ▼|AXP350.58+3.86 (+1.11%) ▲|BA222.28-0.83 (-0.37%) ▼|BAC59.67+0.42 (+0.71%) ▲|BKNG178.39+2.87 (+1.64%) ▲|BLK1,036.11+16.43 (+1.61%) ▲|BMY57.58-0.36 (-0.62%) ▼|BNY151.92-0.34 (-0.22%) ▼|BRK-B493.71-1.74 (-0.35%) ▼|C140.79+1.22 (+0.87%) ▲|CAT952.41+14.02 (+1.49%) ▲|CL92.24+1.23 (+1.35%) ▲|CMCSA23.57+0.23 (+0.96%) ▲|COF201.52+1.42 (+0.71%) ▲|COP109.04+1.02 (+0.94%) ▲|COST916.25+3.28 (+0.36%) ▲|CRM163.32+0.82 (+0.50%) ▲|CSCO121.31+3.00 (+2.54%) ▲|CVS104.15+1.34 (+1.30%) ▲|CVX176.40+2.35 (+1.35%) ▲|DE586.86-6.04 (-1.02%) ▼|DHR199.05+3.07 (+1.57%) ▲|DIS95.62-0.55 (-0.57%) ▼|DUK125.48+0.22 (+0.18%) ▲|EMR138.88+1.08 (+0.78%) ▲|FDX314.69+3.85 (+1.24%) ▲|GD375.06+0.46 (+0.12%) ▲|GE359.27+0.23 (+0.06%) ▲|GEV1,091.57+16.31 (+1.52%) ▲|GILD129.83-5.01 (-3.72%) ▼|GM77.85+1.20 (+1.57%) ▲|GOOG355.03-1.21 (-0.34%) ▼|GOOGL357.18-1.71 (-0.48%) ▼|GS1,055.18-0.79 (-0.07%) ▼|HD343.30+4.57 (+1.35%) ▲|HON226.42+3.00 (+1.34%) ▲|IBM287.56-7.74 (-2.62%) ▼|INTC109.84-2.70 (-2.40%) ▼|INTU274.96+1.58 (+0.58%) ▲|ISRG406.78-4.77 (-1.16%) ▼|JNJ256.98-2.12 (-0.82%) ▼|JPM336.47+1.00 (+0.30%) ▲|KO83.49+0.86 (+1.04%) ▲|LIN529.79+4.23 (+0.80%) ▲|LLY1,188.58-28.37 (-2.33%) ▼|LMT523.22+4.96 (+0.96%) ▲|LOW211.63-1.37 (-0.64%) ▼|LRCX350.33-2.84 (-0.80%) ▼|MA526.74+3.54 (+0.68%) ▲|MCD274.60-1.89 (-0.68%) ▼|MDLZ58.83+0.53 (+0.91%) ▲|MDT83.87+1.48 (+1.80%) ▲|META669.21+37.73 (+5.97%) ▲|MMM157.52+2.18 (+1.40%) ▲|MO71.79+0.20 (+0.28%) ▲|MRK123.54-1.53 (-1.22%) ▼|MS222.28+0.15 (+0.07%) ▲|MSFT385.10+0.74 (+0.19%) ▲|MU979.30-12.34 (-1.24%) ▼|NEE87.96+0.86 (+0.99%) ▲|NFLX73.37-2.10 (-2.78%) ▼|NKE44.37+1.59 (+3.72%) ▲|NOW107.71-1.13 (-1.04%) ▼|NVDA210.96+8.18 (+4.03%) ▲|ORCL140.64-3.08 (-2.14%) ▼|PEP137.38-0.48 (-0.35%) ▼|PFE24.17-0.08 (-0.33%) ▼|PG147.04+0.19 (+0.13%) ▲|PLTR126.79-2.25 (-1.74%) ▼|PM181.62+0.45 (+0.25%) ▲|QCOM189.16-1.95 (-1.02%) ▼|RTX195.93+0.73 (+0.37%) ▲|SBUX106.01-0.40 (-0.38%) ▼|SCHW103.12+1.21 (+1.19%) ▲|SO95.61+0.44 (+0.46%) ▲|SPG218.77-0.94 (-0.43%) ▼|T21.13+0.37 (+1.77%) ▲|TMO527.05+2.34 (+0.45%) ▲|TMUS187.61+6.13 (+3.38%) ▲|TSLA407.76+1.21 (+0.30%) ▲|TXN311.46+2.93 (+0.95%) ▲|UBER74.54+0.19 (+0.26%) ▲|UNH424.62-7.06 (-1.64%) ▼|UNP286.96+1.92 (+0.67%) ▲|UPS112.47+1.73 (+1.56%) ▲|USB62.41+0.51 (+0.82%) ▲|V348.97+0.77 (+0.22%) ▲|VZ42.12+0.59 (+1.41%) ▲|WFC87.16+0.25 (+0.29%) ▲|WMT113.90+1.69 (+1.51%) ▲|XOM138.88+1.42 (+1.03%) ▲|AAPL315.32-0.90 (-0.28%) ▼|ABBV248.08-1.83 (-0.73%) ▼|ABT93.93-0.47 (-0.50%) ▼|ACN135.23-3.83 (-2.75%) ▼|ADBE223.64+0.99 (+0.44%) ▲|AMAT602.50+13.84 (+2.35%) ▲|AMD557.89+11.17 (+2.04%) ▲|AMGN363.39-0.23 (-0.06%) ▼|AMT168.59+3.59 (+2.18%) ▲|AMZN245.34-1.70 (-0.69%) ▼|AVGO399.97-1.14 (-0.28%) ▼|AXP350.58+3.86 (+1.11%) ▲|BA222.28-0.83 (-0.37%) ▼|BAC59.67+0.42 (+0.71%) ▲|BKNG178.39+2.87 (+1.64%) ▲|BLK1,036.11+16.43 (+1.61%) ▲|BMY57.58-0.36 (-0.62%) ▼|BNY151.92-0.34 (-0.22%) ▼|BRK-B493.71-1.74 (-0.35%) ▼|C140.79+1.22 (+0.87%) ▲|CAT952.41+14.02 (+1.49%) ▲|CL92.24+1.23 (+1.35%) ▲|CMCSA23.57+0.23 (+0.96%) ▲|COF201.52+1.42 (+0.71%) ▲|COP109.04+1.02 (+0.94%) ▲|COST916.25+3.28 (+0.36%) ▲|CRM163.32+0.82 (+0.50%) ▲|CSCO121.31+3.00 (+2.54%) ▲|CVS104.15+1.34 (+1.30%) ▲|CVX176.40+2.35 (+1.35%) ▲|DE586.86-6.04 (-1.02%) ▼|DHR199.05+3.07 (+1.57%) ▲|DIS95.62-0.55 (-0.57%) ▼|DUK125.48+0.22 (+0.18%) ▲|EMR138.88+1.08 (+0.78%) ▲|FDX314.69+3.85 (+1.24%) ▲|GD375.06+0.46 (+0.12%) ▲|GE359.27+0.23 (+0.06%) ▲|GEV1,091.57+16.31 (+1.52%) ▲|GILD129.83-5.01 (-3.72%) ▼|GM77.85+1.20 (+1.57%) ▲|GOOG355.03-1.21 (-0.34%) ▼|GOOGL357.18-1.71 (-0.48%) ▼|GS1,055.18-0.79 (-0.07%) ▼|HD343.30+4.57 (+1.35%) ▲|HON226.42+3.00 (+1.34%) ▲|IBM287.56-7.74 (-2.62%) ▼|INTC109.84-2.70 (-2.40%) ▼|INTU274.96+1.58 (+0.58%) ▲|ISRG406.78-4.77 (-1.16%) ▼|JNJ256.98-2.12 (-0.82%) ▼|JPM336.47+1.00 (+0.30%) ▲|KO83.49+0.86 (+1.04%) ▲|LIN529.79+4.23 (+0.80%) ▲|LLY1,188.58-28.37 (-2.33%) ▼|LMT523.22+4.96 (+0.96%) ▲|LOW211.63-1.37 (-0.64%) ▼|LRCX350.33-2.84 (-0.80%) ▼|MA526.74+3.54 (+0.68%) ▲|MCD274.60-1.89 (-0.68%) ▼|MDLZ58.83+0.53 (+0.91%) ▲|MDT83.87+1.48 (+1.80%) ▲|META669.21+37.73 (+5.97%) ▲|MMM157.52+2.18 (+1.40%) ▲|MO71.79+0.20 (+0.28%) ▲|MRK123.54-1.53 (-1.22%) ▼|MS222.28+0.15 (+0.07%) ▲|MSFT385.10+0.74 (+0.19%) ▲|MU979.30-12.34 (-1.24%) ▼|NEE87.96+0.86 (+0.99%) ▲|NFLX73.37-2.10 (-2.78%) ▼|NKE44.37+1.59 (+3.72%) ▲|NOW107.71-1.13 (-1.04%) ▼|NVDA210.96+8.18 (+4.03%) ▲|ORCL140.64-3.08 (-2.14%) ▼|PEP137.38-0.48 (-0.35%) ▼|PFE24.17-0.08 (-0.33%) ▼|PG147.04+0.19 (+0.13%) ▲|PLTR126.79-2.25 (-1.74%) ▼|PM181.62+0.45 (+0.25%) ▲|QCOM189.16-1.95 (-1.02%) ▼|RTX195.93+0.73 (+0.37%) ▲|SBUX106.01-0.40 (-0.38%) ▼|SCHW103.12+1.21 (+1.19%) ▲|SO95.61+0.44 (+0.46%) ▲|SPG218.77-0.94 (-0.43%) ▼|T21.13+0.37 (+1.77%) ▲|TMO527.05+2.34 (+0.45%) ▲|TMUS187.61+6.13 (+3.38%) ▲|TSLA407.76+1.21 (+0.30%) ▲|TXN311.46+2.93 (+0.95%) ▲|UBER74.54+0.19 (+0.26%) ▲|UNH424.62-7.06 (-1.64%) ▼|UNP286.96+1.92 (+0.67%) ▲|UPS112.47+1.73 (+1.56%) ▲|USB62.41+0.51 (+0.82%) ▲|V348.97+0.77 (+0.22%) ▲|VZ42.12+0.59 (+1.41%) ▲|WFC87.16+0.25 (+0.29%) ▲|WMT113.90+1.69 (+1.51%) ▲|XOM138.88+1.42 (+1.03%) ▲|
22.9 C
New York
Sunday, July 12, 2026

Tag: development

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions.

100 Years of DEKRA: Safety in a Changing World

Expert Organization Celebrates Centennial STUTTGART, Germany, July 9, 2025 /PRNewswire/ -- On June 30, 2025, DEKRA celebrated its 100th anniversary – with a clear focus...

100 Years of DEKRA: Safety in a Changing World

Expert Organization Celebrated Centennial  STUTTGART, Germany, July 9, 2025 /PRNewswire/ -- June 30, 2025, DEKRA celebrated its 100th anniversary – with a clear focus on the...

Glucostra Launches Plant-Based Formula with 20 Ingredients for Natural Blood Sugar and Glucose Balance Support

Clean-Label Botanical Formula Aligns with 2025 Demand for the Best Natural Ingredients in Blood Sugar and Glucose Balance SupportSan Francisco
Clean-Label Botanical Formula Aligns with 2025 Demand for the Best Natural Ingredients in Blood Sugar and Glucose Balance SupportSan Francisco

Cohen & Steers Appoints Andrew Shin to lead Institutional Distribution for South Korea

HONG KONG, July 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the appointment of Andrew Shin as Vice President, Head of...

U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for Gastric Cancer

Orphan drug designation highlights the potential for ADRX-0405 to address the high unmet need in gastric cancerSAN DIEGO, July 8, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"),...

CHAMPION IRON PROVIDES NOTICE OF FIRST QUARTER FY2026 RESULTS, CONFERENCE CALL AND WEBCAST DETAILS, AND DATE OF ANNUAL SHAREHOLDERS` MEETING

MONTRÉAL, July 8, 2025 /CNW/ - SYDNEY, July 9, 2025 - Champion Iron Limited (TSX: CIA) (ASX: CIA) (OTCQX: CIAFF) ("Champion" or the "Company") announces...

Yale School of Medicine Receives $27.7 Million Grant Toward Autism Research

NEW HAVEN, Conn., July 8, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research...

Tilson Makes Significant Progress in Plan to Strengthen Business

Company Receives Final Court Approval of Key Business Continuity Motions PORTLAND, Maine, July 8, 2025 /PRNewswire/ -- Tilson Technology Management ("Tilson" or "the Company"), a...

Yale School of Medicine Receives $27.7 Million Grant Toward Autism Research

NEW HAVEN, Conn., July 8, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research to Impact...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical countermeasures, hereby clarifies its update regarding the research study assessing Bucillamine as a potential treatment for nerve agent exposure. This study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, which is investigating pharmacological compounds, including Bucillamine, capable of mitigating nerve agent-induced brain injury.

New Paint Facility at Bombardier’s London Biggin Hill Service Centre Progressing to Plan as Structure Takes Shape

MONTREAL, July 08, 2025 (GLOBE NEWSWIRE) -- Bombardier announced today that the development of a new 51,000 sq. ft. paint facility at the London Biggin Hill Service Centre is progressing in earnest with several key processes completed, including ground stabilization and foundation work on the hangar. The hangar steel framework continues to progress and the cladding works have also commenced. Bromley and Biggin Hill Member of Parliament, Peter Fortune, visited the London Biggin Hill Service Centre on July 4, which provided him with a closer look at the exceptional aerospace expertise at the service centre and the development of its most recent expansion.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment